See more : Marchex, Inc. (MCHX) Income Statement Analysis – Financial Results
Complete financial analysis of Futura Medical plc (FAMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Futura Medical plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hempstract, Inc. (HPST) Income Statement Analysis – Financial Results
- Strategic Energy Resources Limited (SER.AX) Income Statement Analysis – Financial Results
- Ottakringer Getränke AG (OTS.VI) Income Statement Analysis – Financial Results
- Changzhou Almaden Co., Ltd. (002623.SZ) Income Statement Analysis – Financial Results
- Bajaj Holdings & Investment Limited (BAJAJHLDNG.BO) Income Statement Analysis – Financial Results
Futura Medical plc (FAMDF)
About Futura Medical plc
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.10M | 0.00 | 0.00 | 0.00 | 31.78K | 0.00 | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.33M | 24.73K | 19.81K | 25.01K | 0.00 | 19.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.77M | -24.73K | -19.81K | -25.01K | 31.78K | -19.85K | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 57.22% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.05M | 4.13M | 3.77M | 1.93M | 10.05M | 6.04M | 4.10M | 3.51M | 4.78M | 2.37M | 1.98M | 1.44M | 1.00K | 762.00K | 810.00K | 1.40M | 1.52M | 1.08M | 1.55M | 960.00K | 627.00K | 811.00K | 683.00K | 207.00K |
| General & Administrative | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.82K | -4.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -47.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.74M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Cost & Expenses | 10.06M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Interest Income | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.00K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 133.00K | 177.00K | 48.00K | 60.00K | 22.00K | 6.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K | 29.00K | 16.00K |
| Depreciation & Amortization | 130.27K | 24.73K | 19.81K | 25.01K | 20.70K | 19.85K | 13.43K | 6.25K | 6.96K | 4.53K | 3.78K | 2.18K | 4.00K | 8.00K | 11.00K | 16.00K | 15.00K | 11.00K | 13.00K | 16.00K | 13.00K | 14.00K | 9.00K | 1.00K |
| EBITDA | -6.83M | -6.85M | -5.85M | -2.90M | -11.14M | -7.25M | -4.84M | -4.55M | -6.11M | -3.52M | -2.53M | -2.45M | -2.09M | -1.33M | -1.52M | -2.16M | -2.61M | -1.96M | -2.34M | -1.57M | -1.45M | -1.22M | -1.31M | -385.00K |
| EBITDA Ratio | -220.37% | 0.00% | 0.00% | 0.00% | -35,065.34% | 0.00% | -1,335.03% | -2,669.51% | -20,728.20% | -8,018.17% | -681.52% | -3,271.66% | -1,310.76% | -1,047.20% | -3,002.00% | -1,374.67% | -16,320.00% | 0.00% | -110,500.00% | -1,060.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.96M | -6.87M | -5.87M | -2.93M | -11.16M | -7.27M | -4.86M | -4.55M | -6.12M | -3.53M | -2.53M | -2.46M | -2.10M | -1.34M | -1.53M | -2.18M | -2.62M | -2.11M | -2.36M | -1.58M | -1.51M | -1.30M | -1.34M | -392.00K |
| Operating Income Ratio | -224.57% | 0.00% | 0.00% | 0.00% | -35,130.49% | 0.00% | -1,338.73% | -2,673.17% | -20,751.81% | -8,028.47% | -682.54% | -3,274.57% | -1,328.48% | -1,068.80% | -3,052.00% | -1,450.00% | -17,493.33% | 0.00% | -117,800.00% | -1,212.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.21K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 134.00K | 177.00K | 47.00K | 59.00K | -7.00K | -10.00K |
| Income Before Tax | -6.89M | -6.87M | -5.87M | -2.93M | -11.14M | -7.24M | -4.84M | -4.54M | -6.08M | -3.48M | -2.52M | -2.44M | -2.08M | -1.32M | -1.51M | -2.08M | -2.46M | -1.97M | -2.22M | -1.40M | -1.46M | -1.24M | -1.35M | -402.00K |
| Income Before Tax Ratio | -222.25% | 0.00% | 0.00% | 0.00% | -35,060.37% | 0.00% | -1,333.41% | -2,664.54% | -20,621.79% | -7,918.62% | -679.97% | -3,249.92% | -1,313.29% | -1,053.60% | -3,024.00% | -1,385.33% | -16,420.00% | 0.00% | -111,150.00% | -1,076.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -379.07K | -1.02M | -908.60K | -519.09K | -2.22M | -1.36M | -936.34K | -842.25K | -997.04K | -480.69K | -313.68K | -260.79K | -260.00K | -226.00K | -119.00K | -143.00K | -209.00K | -196.00K | -287.00K | -170.00K | -101.00K | -152.00K | -100.00K | -30.00K |
| Net Income | -6.51M | -5.85M | -4.96M | -2.41M | -8.92M | -5.88M | -3.90M | -3.70M | -5.08M | -3.00M | -2.21M | -2.18M | -1.82M | -1.09M | -1.39M | -1.94M | -2.25M | -1.78M | -1.94M | -1.23M | -1.36M | -1.09M | -1.25M | -372.00K |
| Net Income Ratio | -210.03% | 0.00% | 0.00% | 0.00% | -28,067.50% | 0.00% | -1,075.27% | -2,170.15% | -17,239.25% | -6,824.38% | -595.40% | -2,902.20% | -1,148.73% | -872.80% | -2,786.00% | -1,290.00% | -15,026.67% | 0.00% | -96,800.00% | -945.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| Weighted Avg Shares Out | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 43.15M | 40.96M | 30.88M | 27.36M |
| Weighted Avg Shares Out (Dil) | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 45.29M | 40.96M | 30.88M | 27.36M |
Futura Medical hails breakthrough year following Eroxon's global roll-out and FDA approval
Futura Medical PLC (AIM:FUM, OTC:FAMDF) said 2023 was a pivotal year in its commercial journey, marking the successful launch of Eroxon, an over-the-coutner treatment for erectile dysfunction, and the product's approval in the US. Sign-off by the Food & Drug Administration opens...
Futura Medical: Bank sees assesses the importance of contract extension
Liberum, the boutique investment bank, has reiterated its 'buy' recommendation and 131p a share price target for Futura Medical PLC (AIM:FUM, OTC:FAMDF) after it announced that it had extended its licensing deal with Cooper Consumer Health for an additional two years. This...
Futura Medical extends deal with European distributor
Futura Medical PLC (AIM:FUM, OTC:FAMDF), a specialist in sexual health products, has extended its exclusive licensing agreement with distributor Cooper Consumer Health. Effective until January 2029, the new agreement grants Cooper exclusive rights to commercialise Eroxon®, Futura's gel-based erectile dysfunction (ED)...
Futura Medical expands Latin American partnership to include a further 14 countries
In a strategic move to bolster its presence in the Latin American market, Futura Medical PLC (AIM:FUM, OTC:FAMDF) has broadened its licensing agreement with M8 Pharmaceuticals Inc. The expanded contract now includes an additional 14 countries across the Central and...
Futura Medical wins new product award from Boots
Futura Medical's Eroxon erectile dysfunction treatment won the "New Product of the Year, Healthcare" category at the Boots Supplier Awards 2023 following its UK launch earlier this year. James Barder, chief executive said: "Winning the "New Product of the Year, Healthcare" award at...
Futura Medical receives OTC sign-off in Mexico for ED gel
Futura Medical PLC (AIM:FUM, OTC:FAMDF), a pharmaceutical company specialising in innovative sexual health products, has announced OTC Marketing Authorisation for its topical gel Eroxon from the Mexican Secretariat of Health. With this sign-off, the product can be sold in Mexico without...
Futura Medical ED drug roll continues apace
The roll-out of Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s breakthrough erectile dysfunction gel continues apace with sales starting in the company's first market in the Middle East. Eroxon will now be for sale online through the BinSina Pharmacy in the United Arab Emirates, adding...
Futura Medical shares up on patent news - interesting at these levels, says bank
Futura Medical PLC (AIM:FUM, OTC:FAMDF), a pharmaceutical company specialising in sexual health products, has witnessed a 3% increase in its share price after securing a pivotal patent from the European Patent Office for MED3000, its erectile dysfunction (ED) gel. The...
Futura Medical secures patent protection for ED gel out to 2040
Futura Medical PLC (AIM:FUM, OTC:FAMDF), the drug developer specialising in sexual health products, has secured a significant win with the European Patent Office granting protection for MED3000, its erectile dysfunction gel. This patent will offer protection for the product, known...
Futura Medical CEO James Barder discusses FDA approval, market share gains, and plans for Eroxon
In an exclusive with Proactive, James Barder, CEO of Futura Medical PLC (AIM:FUM, OTC:FAMDF), discusses the company's remarkable first half of the year, marked by FDA approval for its erectile dysfunction gel, Eroxon. Barder delves into the financial milestones, market...
Source: https://incomestatements.info
Category: Stock Reports